Skip to main content

AI song generator startups Suno and Udio angered the music industry. Now they’re hoping to join it

CAMBRIDGE, Mass. (AP) — Suno CEO Mikey Shulman pulls up a chair to the recording studio desk where a research scientist at his artificial intelligence company is creating a new song.

The flute line sounds promising.

The percussion needs work.

Neither of them is playing an instrument. They type some descriptive words – Afrobeat, flute, drums, 90 beats per minute – and out comes an infectious rhythm that livens up the 19th century office building where Suno is headquartered in Cambridge, Massachusetts. They toggle some editing tools to refine the new track.

Much like early experiences with ChatGPT or AI text-to-image generators, trying to make an AI-generated song on platforms like Suno or its rival, Udio, can seem a little like magic. It takes no musical skills, practice or emotional wellspring to conjure up a new tune inspired by almost any of the world’s musical traditions.

But the process of training AI on beloved musicians of the past and present to produce synthetic approximations of their work has angered the music industry and brought much of its legal power against the two startups.

Now, after their users have flooded the internet with millions of AI-generated songs, some of which have found themselves on streaming services like Spotify, the leaders of Suno and New York-based Udio are trying to negotiate with record labels to secure a foothold in an industry that shunned them.

“We have always thought that working together with the music industry instead of against the music industry is the only way that this works,” said Shulman, who co-founded Suno in 2022. “Music is so culturally important that it doesn’t make sense to have an AI world and a non-AI world of music.”

Sony Music, Universal Music and Warner Records sued the two startups for copyright infringement in 2024, alleging that they were exploiting the recorded works of their artists.

Since then, the pair have strived to make peace with the industry. Suno, now valued at $2.45 billion, last year struck a settlement with Warner, and Udio has signed licensing agreements with Warner, Universal and independent label Merlin. Only one major label, Sony, has not settled with either startup as the lawsuits move forward in Boston and New York federal courts. Suno also faces legal challenges in Europe brought by groups representing music creators.

The first of the settlement deals, between Udio and Universal, led to an exodus of frustrated Udio users who were blocked from downloading their own AI-generated tracks. But Udio CEO Andrew Sanchez said he’s optimistic about what the future will bring as his company adapts its business model to let fans of willing artists use AI to play with and potentially alter their works.

“Having a close relationship with the music industry is elemental to us,” Sanchez said in an interview. “Users really want to have an anchor to their favorite artists. They want to have an anchor to their favorite songs.”

Many professional musicians are skeptical. Singer-songwriter Tift Merritt, co-chair of the Artists Rights Alliance, recently helped organize a “Stealing Isn’t Innovation” campaign by artists — including Cyndi Lauper and Bonnie Raitt — to urge AI companies to pursue licensing deals and partnerships rather than build platforms without regard for copyright law.

“The economy of AI music is built totally on the intellectual property, globally, of musicians everywhere without transparency, consent, or payment. So, I know they value their intellectual property, but ours has been consumed in order to replace us,” Merritt said in an interview in Raleigh, North Carolina.

Shulman contends technology “evolves very often faster than the law,” and his company tries to be thoughtful about “not breaking the law” but also “deliver products that the world really wants.”

Suno CEO doesn’t really think ‘people don’t enjoy’ making music

When the music industry first confronted Suno over alleged copyright infringement, the company’s antagonistic response alienated professionals like Merritt.

Symbolizing the divide was a clip last year in which Shulman was quoted as saying, “it’s not really enjoyable” to make music most of the time. Shulman started learning piano at age 4 but later dropped it. He took up bass guitar at 12, playing in rock bands in high school and college. He said that experience gave him some of the best moments of his life.

“You need to get really good at an instrument or really good at a piece of production software,” Shulman said on the “The Twenty Minute VC” podcast. “I think the majority of people don’t enjoy the majority of the time they spend making music.”

“Clearly, I wish I had said different words,” Shulman told the AP. The context, he added, was that “to produce perfect music takes a lot of repetitions and not all of those minutes are the most enjoyable bits of making music. On the whole, obviously, music is amazing. I play music every day for fun.”

Udio CEO pitches his company as the friendly alternative

Sanchez, the Udio CEO, also loves making music. He’s an opera-loving tenor who’s sung in choirs and grew up crooning Luciano Pavarotti in his family’s home in Buffalo, New York.

Founded in 2023 by a group that included several AI researchers from Google, the startup now employs about 25 people. It has fewer users and raised less venture capital than Suno, which likely gave Udio a stronger incentive to be first to settle with record labels, said copyright lawyer Brandon Butler.

“A service (like Suno) that gets more venture backing is in some sense hungrier to find revenue streams and more on the hook to all those backers to make sure that they achieve profitability, which would make settling and compromising less attractive,” said Butler, director of the copyright advocacy group Re:Create. “Whereas a company with fewer backers, with less capital, with less access would be weaker and less able to resist the risk that they’re incurring by being involved in litigation.”

Still, Udio embraces its underdog status.

“So many tech companies actively cultivate this I-am-a-tech-company-crusader and that’s part of their identity,” Sanchez said. “That alienates people who are creative and I am uniformly opposed to that.”

Sanchez said he knows not every artist is going to embrace AI, but he hopes those who leave the room after talking with him realize he’s not imposing a kind of “AI bravado.”

“If you took what we’re doing and pretended that the word AI wasn’t a part of it, people would be like, ‘Oh my gosh. This is so cool.’”

Some see potential in AI-assisted music creation

In the basement office of his Philadelphia, Mississippi home, Christopher “Topher” Townsend is a one-man band, making and marketing Billboard-chart-topping gospel music — none of which he sings himself — and doing it in record time.

The rapper, whose lyrics reflect his political conservatism, downloaded Suno in October and, within days, created Solomon Ray, a fictional singer that Townsend calls an extension of himself.

Townsend uses ChatGPT to write lyrics, Suno to generate songs and other AI tools to create cover art and promotional videos under the Solomon Ray name.

“I can see why artists would be afraid,” Townsend said. ”(Solomon Ray) has an immaculate voice. He doesn’t get sick. You know, he doesn’t have to take leave, he doesn’t get injured and he can work faster than I can work.”

Trying to dispel that fear for aspiring artists is Jonathan Wyner, a professor of music production and engineering at the Berklee College of Music in Boston, who sees generative AI as just another tool.

“To the creative musician, AI represents both enormous potential benefits in terms of streamlining things and frankly making kinds of music-making possible that weren’t possible before, and making it more accessible to people who want to make music,” he said.

Such a vision remains a tough sell for artists who feel their work has already been exploited. Merritt says she’s particularly concerned about labels making deals with AI companies that leave out independent artists. An open letter she co-signed this week says “many in our community are embracing responsible AI as a tool for creation” but targets Suno as a “smash and grab” business that artists should avoid.

“Artists need to know the difference – all AI platforms are not the same, and Suno, which is being sued for copyright infringement, is not a platform artists should trust,” says the letter from Merritt and six others.

—————-

O’Brien reported from Cambridge, Massachusetts and New York. Ngowi reported from Cambridge and Somerville, Massachusetts. AP journalists Sophie Bates in Philadelphia, Mississippi and Allen G. Breed in Raleigh, North Carolina, contributed to this report.

When you have advanced prostate cancer: What living with the disease looks like

(CNN) — “How long do I have to live ?”When I tell a patient he has prostate cancer, this is usually what he asks me first.With early-stage or low-grade prostate cancer, I can offer strong reassurance: Your life expectancy is good — expect a five-year relative survival rate of greater than 99% with treatment. Simply put, most men will not die from low-grade prostate cancer.However, once the cancer has spread outside the prostate to the bones and other organs the answer becomes more difficult. Treatment has changed dramatically over the past decade for advanced prostate cancer. New drugs, better imaging and the earlier use of combined therapies are helping men live longer.In a video released July 15, former President Joe Biden gave an update on his prostate cancer, saying he was receiving treatments that have been going well. In May 2025, Biden officially announced that he had an aggressive form of prostate cancer that had spread to his bones. Since then, based on official updates, he has continued hormone therapy, completed a course of radiation and maintained a public presence.His diagnosis brought renewed attention to prostate cancer screening and treatment. Now, more than a year later, his cancer journey offers an opportunity to examine what has changed in the treatment of advanced prostate cancer — and the hope these offer men living with the disease.I recently saw a patient who was diagnosed three years ago with cancer that had already spread to multiple areas in his bones. Since then, he has taken cruises, traveled with his family and spent weekends babysitting his grandchildren.He gets tired and cannot garden the way he once did. But he is still alive and considers every day a blessing. His experience, and what we see with Biden, shows what living with metastatic prostate cancer can look like today.Understanding survival ratesIf they haven’t asked their doctor already, many patients go online and find five-year survival rates, but every number they may find online comes with a huge asterisk.The American Cancer Society reports five-year relative survival of greater than 99% when prostate cancer is found in or near the prostate. The figure drops to 38% when it has reached distant parts of the body.But that number is based on large groups of men treated years ago. It does not fully reflect the impact of newer treatments — or account for an individual man’s age, overall health and response to therapy.Survival statistics describe groups of patients but do not predict what will happen to one person. That is why the 38% figure cannot tell us how long Biden — or any individual patient — will live. These patients’ outlook depends on details of their cancer and how they are responding to treatments.It’s treated more aggressively nowA man diagnosed with metastatic prostate cancer a decade ago and a man diagnosed today would not receive the same treatment. The thinking now is to use our best treatments early instead of holding back.For years, doctors began with hormone therapy — usually injections that lower testosterone — and saved other treatments until the cancer stopped responding.Today, those injections are often combined from the start with a newer hormone-blocking drug and/or chemotherapy. These combinations have helped men live longer and are one of the biggest shifts of the past decade.What Biden’s diagnosis told usThere are three details about Biden’s cancer that help doctors like me understand how aggressive it is and how to manage it effectively. Official statements highlighted that his cancer had a Gleason score of 9. The cancer had spread to his bones, and it was labeled as hormone-sensitive.The Gleason score is assigned after a pathologist examines biopsy samples. Scores typically range from 6 to 10, with higher numbers indicating more aggressive cancer. A score of 9 falls into the most aggressive category. However, the score alone cannot tell us whether the cancer has spread outside the prostate.When prostate cancer spreads, the most common destination is the bones — particularly the spine, pelvis and ribs. It can also reach organs such as the lungs or liver. Once it has reached distant parts of the body, it is generally not curable, but treatment can put a brake on it for years.Prostate cancer can also be hormone-sensitive or hormone-resistant. Because it typically relies on testosterone to grow, lowering the hormone or blocking its effects can help control the cancer. Hormone-sensitive means it still responds to these treatments.Over time, most advanced or metastatic prostate cancers find ways to grow despite low testosterone levels, which mean they are now hormone-resistant. Lowering testosterone alone is no longer enough to control the cancer, so doctors have to turn to additional therapies.Knowing if the cancer has spreadThe most sensitive imaging test available today is a PSMA PET scan. It uses a radioactive tracer that seeks out a protein found on the surface of prostate cancer cells. Areas containing cancer may appear as bright spots, helping identify where the cancer has spread. The American Urological Association supports using this imaging test to determine whether high-risk prostate cancer has spread and to help establish its stage.A traditional bone scan, used for decades, highlights areas where bone is reacting to injury or disease. It remains an alternative imaging option, but PSMA PET is increasingly replacing its use.What areas light up and where matter when deciding on treatments. A single spot in the spine and cancer that has spread to the liver are both called stage 4, but they are not the same disease and may not be treated the same way.Doctors also consider how much cancer has spread. We label it as “low-volume” disease when the cancer has reached a limited number of areas. High volume is when the spread is more widespread or has reached other organs such as the liver or lungs.Both require treatment that works throughout the body. Treatment for metastatic disease generally includes therapy that works throughout the body. For men with low-volume disease, adding radiation to the prostate may also help them live longer.Biden has completed a course of radiation, but his team has not disclosed what area was treated or enough detail to determine whether his cancer would be considered low- or high-volume.Treatment has become more preciseBeyond starting more treatments earlier, doctors can increasingly tailor therapy to the biology of an individual man’s cancer. We can now test both the tumor and a patient’s own DNA for mutations that help guide treatment.Roughly 1 in 10 men with metastatic prostate cancer carries an inherited mutation affecting the body’s ability to repair DNA. The best known are BRCA1 and BRCA2, the same genes linked to some breast and ovarian cancers.Certain mutations found in the tumor or inherited DNA may make targeted drugs called PARP inhibitors an option. If a mutation is inherited, it also gives family members information they can act on through genetic counseling, testing and earlier screening.Another advance is radioligand therapy. If a scan shows that cancer cells carry a protein called PSMA, doctors can attach radiation to a molecule that seeks out that protein. Delivered through an IV, it targets cancer cells throughout the body. This approach was expanded last year to more men whose cancer had become hormone resistant.Living longer can come with costsEvery treatment can cause side effects. With hormone therapy, one of the first is often hot flashes, similar to what women experience during menopause. These are not dangerous, but they can affect a man’s quality of life.Fatigue is also common. Testosterone helps maintain muscle, so lowering it can reduce strength and energy. Regular walking and resistance training can help preserve muscle and reduce fatigue.The side effect almost no one talks about is loss of sex drive or low libido. At diagnosis, most men are thinking about staying alive, not their libido. But months later, it often matters. It is worth discussing with your care team and your partner rather than assuming it is simply the price of treatment.The side effect I worry about most is weaker bones. Low testosterone reduces bone density, while cancer deposits can weaken the bone’s structure. Follow-up care should include exercise, a bone-density scan, and ensuring adequate levels of calcium and vitamin D. For men with hormone-resistant cancer that has spread to bone, bone-protecting drugs can reduce the risk of fractures and other complications.New or worsening back pain, especially with leg weakness, numbness or trouble controlling the bladder or bowels? These could mean the cancer is pressing on the spinal cord. It is a true medical emergency that requires immediate attention.Cancer care requires a team approachIdeally, several doctors work together to coordinate a patient’s care. The urologist is often the starting point. A medical oncologist manages treatments that work throughout the body, while a radiation oncologist targets specific areas, whether that is the prostate itself or a painful bone lesion. The primary care doctor helps protect the patient’s heart and bones and looks after the person’s overall health.A man’s age, other medical conditions, ability to tolerate side effects and goals for treatment all shape treatment plans. Two men with nearly identical test results may be offered — or choose — different paths based on their health and priorities.Good communication among doctors is essential, but gaps can happen. Being your own advocate means knowing who is on your care team, asking questions and understanding your options.I also recommend bringing someone you trust to important visits for support and to take notes and help you remember what was discussed.More treatments, better testing offer hopeFor men worried about prostate cancer, talk with your health care provider about the benefits and risks of PSA testing. Black men and those with a strong family history should begin that conversation in their 40s. New urinary symptoms are often not cancer, but they still deserve attention, as does blood in the urine or semen, unexplained weight loss and/or persistent back or bone pain.For men living with advanced prostate cancer, there is reason for hope. There are more treatments and better testing than there were a decade ago, and good care pays attention to how a man feels, not just to what his scans show.The-CNN-Wire™ & © 2026 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.
Read Next Story